Ovarian Cancer

Mostafa Eyada, MD, University of Texas, Medical Branch

Videos

Bevacizumab Plus Oral Cyclophosphamide Demonstrated Safety, Efficacy Among Patients With Recurrent Platinum-Resistant Ovarian Cancer

06/19/2024

Mostafa Eyada, MD

Mostafa Eyada, MD, describes a retrospective analysis assessing the safety and efficacy of bevacizumab plus oral cyclophosphamide among patients with recurrent high-grade platinum-resistant ovarian, fallopian tube, and primary peritoneal...

Mostafa Eyada, MD, describes a...

06/19/2024

Oncology

Frederik Marmé, PhD, Heidelberg University

Videos

Atezolizumab Plus Chemotherapy and Bevacizumab Did Not Improve Survival For Patients With Recurrent Platinum-Resistant Ovarian Cancer

06/13/2024

Frederik Marmé, MD, PhD

According to phase 3 data, the addition of atezolizumab to the standard regiment of bevacizumab plus non-platinum chemotherapy did not improve overall survival or progression-free survival among patients with recurrent platinum-resistant...

According to phase 3 data, the...

06/13/2024

Oncology

Conference Coverage

Batiraxcept Plus Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey ;

According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.

According to phase 2 results,...

06/13/2024

Oncology

Conference Coverage

Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey ;

Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.

Results from the phase 3 SCORES...

06/13/2024

Oncology

Quiz: Does Hydroxychloroquine Plus Itraconazole Display Antitumor Activity in Advanced EOC?

07/29/2021

Although hydroxychloroquine plus itraconazole was feasible in heavily pre-treated patients with platinum-resistant epithelial ovarian cancer, the regimen did not demonstrate antitumor activity.

Although hydroxychloroquine plus...

07/29/2021

Oncology

Videos

Real-World Utilization of Second-Line Maintenance Therapy for Advanced Ovarian Cancer

07/19/2021

Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.

Katrine Wallace, PhD, MS,...

07/19/2021

Journal of Clinical Pathways

Conference Coverage

Real-World PFS Among Patients With Ovarian Cancer Receiving First-Line Maintenance Therapy vs Active Surveillance

07/14/2021

Though most patients with ovarian cancer do not receive first-line maintenance therapy, those who do may be more likely to experience improved PFS.

Though most patients with...

07/14/2021

Journal of Clinical Pathways